Iterum Therapeutics financials at a glance

+ Portfolio

The revenue of Iterum Therapeutics is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -3.38 Dollars per share in 2023, which was 3.89 lower than 2021. And about -9.0E-5 billion Dollars are reported as free cash flow in the financials of Iterum Therapeutics 2023. No dividends were paid to the shareholders of the Iterum Therapeutics stock NasdaqCM:ITRM in the financial year 2023.

$0.00M

Revenue

$-1.87

Earnings Per Share

0.00%

Gross Margin %

$0.00M

Free Cash Flow

Revenue

0.00

Earnings Per Share

-1.87

Gross Margin %

0.00

Free Cash Flow

0.00

Financials

Year	Year	TTM	2022	2021	2020	2019	2018
Rev.	Revenue	N/A	$0.00M	$0.00M	$0.00M	$0.04M	$0.87M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-2.44	$-1.87	$-1.80	$-21.00	$-,106.50	$-,106.65
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	0	0	0
Sha.	Shares	N/AM	12.71M	12.19M	11.77M	0.99M	0.96M
OCF	Operating Cash Flow	N/A	$0.00M	$0.00M	$-54.53M	$-78.89M	$-75.89M
FCF	Free Cash Flow	N/A	$0.00M	$0.00M	$-54.54M	$-78.91M	$-75.98M
FCFS	Free Cash Flow Per Share	$-2.42	$-1.51	$-1.46	$-2.27	$-5.64	$-8.86

Iterum Therapeutics financials at a glance

Financials

Discover